Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates.

Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates.

Despite the potential for the chemokine class as therapeutic targets in immune mediated disease, success has been limited. Many chemokines can bind to multiple receptors and many receptors have multiple ligands, with few exceptions. One of those exceptions is CCL20, which exclusively pairs to CCR6 a...

Full description

Bibliographic Details
Main Authors: Susan B Laffan, Andrew S Thomson, Shing Mai, Cindy Fishman, Takahito Kambara, Kiran Nistala, James T Raymond, Shugui Chen, Thulasi Ramani, Laura Pageon, Rodd Polsky, Mark Watkins, Gemma Ottolangui, John R White, Curtis Maier, Michael Herdman, Gerben Bouma
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0231655

Internet

https://doi.org/10.1371/journal.pone.0231655

Similar Items